Pavan Rawat

@pavan.rawat.6715

Indore

5+ Years of experience

SEBI Registration INH000025966

Trade Ideas

251

Opinions

225

Followers

Expertise

Quantitative

Growth

Technical

Index Strategies

Market Commentary

Futures & Options

Technical Analysis

Trade Facts

Total Trades

Missed Trades

Profit Trades

Accuracy

Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 1 hour ago

REC Limited in Focus as PFC Merger Advances

RECLTD

REC Limited is in focus after receiving no-objection letters from the National Stock Exchange (NSE) and BSE on October 19, 2026, for its proposed merger with Power Finance Corporation (PFC). The merger aims to create a large power-sector financing entity with a combined loan book exceeding ₹11 lakh crore. The transaction remains subject to the necessary regulatory and other approvals. Investor attention is also shifting towards REC’s upcoming board meeting scheduled for October 26, 2026, to consider the financial results for the quarter and half-year ended September 30, 2026, along with a possible second interim dividend for FY27. In Q1 FY27, REC reported consolidated net profit of approximately ₹4,193 crore, while its net interest margin stood at 3.34%, reflecting continued strength in its power-sector lending operations. Going forward, investors will monitor the Q2 earnings, potential dividend announcement and progress towards completing the PFC merger. The consolidation could offer opportunities for greater scale and operational efficiency, while regulatory approvals, integration plans and future lending growth will remain important factors influencing REC’s stock performance.

shared an insight ⚡️ 15 hours ago

anara Bank Reports 8.4% Growth in Q2 Profi

CANBK

Canara Bank reported an 8.4% year-on-year increase in net profit to ₹5,175 crore for the second quarter of FY27, compared with ₹4,774 crore in the corresponding quarter last year. Net interest income (NII) rose 20.4% to approximately ₹11,005 crore, supported by growth in core banking income. The results highlight the bank’s continued improvement in lending operations and profitability. The bank’s global business increased 15.88% year-on-year to approximately ₹30.72 lakh crore as of September 30, 2026. Global advances grew 19.46%, while global deposits increased 13.13%. Asset quality also improved, with the gross non-performing asset (GNPA) ratio declining to 1.33% from 2.35% a year earlier, while the net NPA ratio stood at 0.30%. However, lower treasury income remained a concern for overall earnings growth. Going forward, investors will monitor credit growth, deposit mobilisation, net interest margins and treasury income. Improving asset quality and strong NII growth provide positive signals, but the bank’s ability to sustain profitability amid changing interest rates and funding costs will remain important. Market participants will also track management commentary on business expansion and capital-raising plans for further direction on the stock.

234

shared an insight ⚡️ 19 hours ago

Dr Reddy’s Laboratories Ltd. TO RESUME SEMAGLUTIDE

DRREDDY

Dr Reddy’s Laboratories is preparing to resume semaglutide supplies across key international markets from November after resolving manufacturing challenges that delayed the product’s rollout earlier this year. Canada is expected to contribute the largest share of initial sales volumes as the company looks to meet demand that built up during the temporary suspension. During a media interaction, the company’s management confirmed that it had addressed issues related to the production scale-up of semaglutide active pharmaceutical ingredient. Management said the company had voluntarily suspended marketing activities when the scale-up problem emerged rather than continuing sales amid production challenges. With the issue now resolved, Dr Reddy’s is preparing to re-enter the affected markets. The manufacturing disruption had a financial impact in the June quarter, when the company recorded a provision of Rs 240 crore towards inventory and other costs associated with the semaglutide API issue. However, management does not anticipate a similar financial burden in the coming quarters. The Hyderabad-based pharmaceutical company has secured semaglutide approvals in 10 countries, including India and Canada. Eight of these approvals are from emerging markets across Latin America, Africa and the Middle East, providing scope for further international expansion. Canada is expected to be the primary market during the initial phase of the relaunch. Dr Reddy’s plans to resume supplies in the current quarter and cater to demand that accumulated while the product was temporarily withdrawn.

276

What are the top stock recommendations by Pavan Rawat?

Pavan Rawat regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include RECLTD, CANBK and DRREDDY. Explore Pavan Rawat's complete list of posts and trade views on their StockGro profile.

How can I follow Pavan Rawat's latest investment insights?

You can follow Pavan Rawat's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is Pavan Rawat's investment strategy?

Pavan Rawat follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has Pavan Rawat been a SEBI-registered Research Analyst (RA)?

Pavan Rawat has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see Pavan Rawat's past performance and stock picks?

You can check Pavan Rawat's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact Pavan Rawat for stock market advice?

For stock market guidance from Pavan Rawat, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is Pavan Rawat's track record in predicting market movements?

Pavan Rawat has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for Pavan Rawat?

Pavan Rawat is a SEBI-registered Research Analyst with the SEBI Registration INH000025966. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.

Be Financially Free with StockGro